This paper addresses how the speed of the creation and function of innovation ecosystems can be increased in the face of global challenges. It provides a case study of the successful and rapid development of a Covid-19 vaccine by the University of Oxford and the pharmaceutical company, AstraZeneca: a vaccine that saved millions of lives. Its review of the innovation ecosystems literature reveals there has been little consideration of the speed of development at innovation ecosystem scale, and on the role of universities with public good objectives within innovation ecosystems. The case study, primarily based on interviews supplemented by some data analysis, provides a deep, detailed, and contextualised analysis of the development of a successful vaccine within an innovation ecosystem. It finds that speed was enabled by concurrent development, such that the usual processes for vaccine development were significantly compressed without significantly diminished safety; also evident was shared and greater tolerance for risk across the ecosystem, high levels of trust, and skilful communications. The discussion considers the implications of the study, including lessons for the study of innovation ecosystems and for government and university policies. It offers reflections on the paper’s contributions, its shortcomings, and implications for future research.